Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StrateGIST 3: IDRX-42 (GSK6042981) vs sunitinib in metastatic/unresectable GIST after imatinib
jRCT2031250371Phase 3Recruiting
- Sponsor
- GSK
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of IDRX-42 in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by GSK. Primary endpoint: Progression-free survival by blinded independent central review (PFS by BICR). Started Oct 2025; status: recruiting.
02
Drugs
IDRX-42
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on jRCT2031250371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250371.